Needham & Company Downgrades Aeglea Biotherapeutics (AGLE) to Hold
Tweet Send to a Friend
Needham & Company analyst Gil Blum downgraded Aeglea Biotherapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
